EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pasithea Therapeutics's enterprise value is $-8.60 Mil.
Pasithea Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil. Therefore, Pasithea Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Pasithea Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 4 years, the highest EV-to-Revenue of Pasithea Therapeutics was -531.71. The lowest was -2524.86. And the median was -1967.13.
KTTA's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.54 * Ranked among companies with meaningful EV-to-Revenue only.
Pasithea Therapeutics EV-to-Revenue Historical Data
The historical data trend for Pasithea Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pasithea Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Pasithea Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pasithea Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Pasithea Therapeutics's EV-to-Revenue falls into.
Pasithea Therapeutics's current Enterprise Value is $-8.60 Mil.
Pasithea Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pasithea Therapeutics's share price for today is $2.65.
Pasithea Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pasithea Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Pasithea Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KTTA has been successfully added to your 